Please ensure Javascript is enabled for purposes of website accessibility

Is This Sizzling IPO Stock Getting Too Hot to Handle?

By Keith Speights – Oct 9, 2020 at 6:09AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

AmWell is riding high after its IPO last month. Can it keep the momentum going?

Most investors would say that a stock is pretty hot if it went up more than 50% in a year, but what about one that soars even higher in less than one month? Such a stock would be considered sizzling hot.

American Well (AMWL 4.17%) definitely fits that definition. Its shares are up nearly 60% since the telehealth company's initial public offering (IPO) on Sept. 17. Could AmWell go even higher, or is the stock now too hot to handle?

A person sitting on sofa consulting with a healthcare professional on a laptop.

Image source: Getty Images.

A nosebleed valuation and a potential problem

AmWell looks expensive. The company's market cap tops $8 billion with no profits yet. As a result, you can throw earnings-based valuation metrics out the window.

The healthcare stock currently trades at 19 times trailing-12-month sales. Many investors would consider that nosebleed valuation territory. 

Yes, AmWell's sales are growing rapidly. However, much of the company's recent growth has been fueled by the COVID-19 pandemic. AmWell reported that its average monthly visit volumes quadrupled in the three months ending June 30, 2020, compared to the first quarter of this year. Its average monthly active providers skyrocketed 400% quarter over quarter. 

But can that growth trajectory continue? Sooner or later, the COVID-19 pandemic will be over. Safe and effective vaccines could be widely available in the U.S. next year. The pandemic has also led to the relaxation of some regulatory and reimbursement barriers for telehealth. It's possible that when the healthcare crisis is over, those barriers will be put back into place.

AmWell's shares are priced for perfection. If its growth rate slows significantly as coronavirus concerns fade, restrictive regulations return, and reimbursement hurdles reemerge, the stock will almost certainly plunge.

Mountains or molehills?

Even AmWell bulls would likely agree that the stock isn't cheap. They might not even dispute that the end of the pandemic could present some challenges for the company. However, proponents of the telehealth stock would also almost certainly argue that these issues are molehills and not mountains.

For one thing, AmWell's revenue increased more than 30% year over year in 2019, before the COVID-19 outbreaks began. That's in line with the revenue growth generated by top telehealth stock Teladoc Health (TDOC 8.70%), and AmWell's shares trade at a lower price-to-sales ratio than Teladoc's shares.

The COVID-19 pandemic has certainly poured fuel on the fire with the adoption of telehealth. That fire isn't likely to die down once the pandemic ends. On the contrary, AmWell's recent annual physician and consumer survey indicates that telehealth use will accelerate when the COVID-19 crisis is over.

What about potential reinstatement of regulatory and reimbursement challenges? That could hurt AmWell in some ways. However, the overall impact could be positive for the company. In particular, the renewed focus on enforcement of privacy laws could push some smaller telehealth players out of the market, paving the way for big players like AmWell and Teladoc to consolidate their market share.

The heat is on

Investors should focus more on the future than the present or the past. My view is that AmWell's future appears to be very bright.

The company estimates that the total addressable market for its telehealth subscription services for health plans and health systems is around $12.4 billion per year. Add to that total another $22.1 billion addressable market for AmWell's AMG staffing network. Currently, AmWell's share of these markets stands well below 1%. 

Keep in mind that these markets are growing and will almost certainly continue to do so for years to come. I think that AmWell is well-positioned to be a big telehealth winner over the long run. This sizzling IPO stock isn't too hot to handle. Instead, its opportunities are arguably too hot to ignore.

Keith Speights owns shares of Teladoc Health. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

American Well Corporation Stock Quote
American Well Corporation
$4.00 (4.17%) $0.16
Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
$28.12 (8.70%) $2.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.